Jul 30 |
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
|
Jul 29 |
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
|
Jul 28 |
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
|
Jul 11 |
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
|
Jun 21 |
Is Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) the Best Halal Stock According to Hedge Funds?
|
May 15 |
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
May 15 |
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
|
May 14 |
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
|
May 14 |
Acumen Pharmaceuticals GAAP EPS of -$0.25
|
May 14 |
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
|